Movement Alert｜XTALPI Intraday Rise 5.36%, Innovation Pharma Momentum Builds Ahead of ESMO

Market Focus

Oct 06

On October 6, XTALPI rose 5.36% in regular trading, trading at HK$8.26/share, with Turnover of HK$85.92 million.

The movement aligns with sector-wide gains across innovation pharma stocks following ESMO conference disclosures about Chinese drug firms' breakthroughs. Among 29 Chinese-developed drugs featured in key trials announced for the upcoming oncology congress, the industry-wide recognition highlights the growing research capabilities that extend to AI drug discovery solutions providers like XTALPI.

XTALPI has recently demonstrated accelerated R&D capabilities through its subsidiary's PCC-nominated HIV drug candidate and strategic partnership with Stanford University leveraging its AI-powered PACE drug discovery platform. Combined with active share buybacks and the Board Chairman's plan to purchase additional shares, these developments signal confidence in the company's technology pipeline.

(This content is based on market information for educational purposes only, not investment advice.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/news/1110886230"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1110886230\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1110886230?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-06 10:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1110886230","market":"hk","top_or_hot":-1,"title":"Movement Alert｜XTALPI Intraday Rise 5.36%, Innovation Pharma Momentum Builds Ahead of ESMO","media":"Market Focus","content":"<p><p>On October 6, XTALPI rose 5.36% in regular trading, trading at HK$8.26/share, with Turnover of HK$85.92 million.<p>The movement aligns with sector-wide gains across innovation pharma stocks following ESMO conference disclosures about Chinese drug firms' breakthroughs. Among 29 Chinese-developed drugs featured in key trials announced for the upcoming oncology congress, the industry-wide recognition highlights the growing research capabilities that extend to AI drug discovery solutions providers like XTALPI.<p>XTALPI has recently demonstrated accelerated R&D capabilities through its subsidiary's PCC-nominated HIV drug candidate and strategic partnership with Stanford University leveraging its AI-powered PACE drug discovery platform. Combined with active share buybacks and the Board Chairman's plan to purchase additional shares, these developments signal confidence in the company's technology pipeline.</p><p>(This content is based on market information for educational purposes only, not investment advice.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜XTALPI Intraday Rise 5.36%, Innovation Pharma Momentum Builds Ahead of ESMO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜XTALPI Intraday Rise 5.36%, Innovation Pharma Momentum Builds Ahead of ESMO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-06 10:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 6, XTALPI rose 5.36% in regular trading, trading at HK$8.26/share, with Turnover of HK$85.92 million.<p>The movement aligns with sector-wide gains across innovation pharma stocks following ESMO conference disclosures about Chinese drug firms' breakthroughs. Among 29 Chinese-developed drugs featured in key trials announced for the upcoming oncology congress, the industry-wide recognition highlights the growing research capabilities that extend to AI drug discovery solutions providers like XTALPI.<p>XTALPI has recently demonstrated accelerated R&D capabilities through its subsidiary's PCC-nominated HIV drug candidate and strategic partnership with Stanford University leveraging its AI-powered PACE drug discovery platform. Combined with active share buybacks and the Board Chairman's plan to purchase additional shares, these developments signal confidence in the company's technology pipeline.</p><p>(This content is based on market information for educational purposes only, not investment advice.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02228","symbol_name":"晶泰控股","start_time":0,"source_url":"","article_id":"1110886230","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1110886230","pubTimestamp":1791253546,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 6, XTALPI rose 5.36% in regular trading, trading at HK$8.26/share, with Turnover of HK$85.92 million.The movement aligns with sector-wide gains across innovation pharma stocks following...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02228":"晶泰控股"},"translate_title":"走势提醒|XTALPI盘中上涨5.36%，创新制药势头领先ESMO","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02228":1},"content_text":"On October 6, XTALPI rose 5.36% in regular trading, trading at HK$8.26/share, with Turnover of HK$85.92 million.The movement aligns with sector-wide gains across innovation pharma stocks following ESMO conference disclosures about Chinese drug firms' breakthroughs. Among 29 Chinese-developed drugs featured in key trials announced for the upcoming oncology congress, the industry-wide recognition highlights the growing research capabilities that extend to AI drug discovery solutions providers like XTALPI.XTALPI has recently demonstrated accelerated R&D capabilities through its subsidiary's PCC-nominated HIV drug candidate and strategic partnership with Stanford University leveraging its AI-powered PACE drug discovery platform. Combined with active share buybacks and the Board Chairman's plan to purchase additional shares, these developments signal confidence in the company's technology pipeline.(This content is based on market information for educational purposes only, not investment advice.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}